Acamprol 333 mg: Effective Support for Alcohol Dependence Recovery
| Product dosage: 333 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.08 | $62.27 (0%) | 🛒 Add to cart |
| 60 | $1.89 | $124.54 $113.49 (9%) | 🛒 Add to cart |
| 90 | $1.43 | $186.81 $128.55 (31%) | 🛒 Add to cart |
| 120 | $1.19 | $249.07 $142.62 (43%) | 🛒 Add to cart |
| 180 | $1.05
Best per pill | $373.61 $188.81 (49%) | 🛒 Add to cart |
Synonyms | |||
Acamprol 333 mg is a prescription medication specifically formulated to aid in the maintenance of abstinence from alcohol in patients with alcohol dependence. It is indicated as part of a comprehensive management program that includes psychosocial support. The active ingredient, calcium acetylhomotaurinate, is believed to help restore the disrupted balance of neurochemicals in the brain associated with chronic alcohol use. By modulating neurotransmitter systems, Acamprol 333 mg helps reduce the craving for alcohol and alleviate the distress of post-withdrawal syndrome, supporting long-term recovery efforts under medical supervision.
Features
- Each tablet contains 333 mg of calcium acetylhomotaurinate
- Delayed-release tablet formulation for consistent effect
- Administered orally, typically two tablets three times daily
- Requires prescription and medical supervision
- Not associated with abuse potential or sedation
- Compatible with most comprehensive alcohol dependence treatment programs
Benefits
- Supports reduction of alcohol craving and consumption
- Helps maintain abstinence as part of a comprehensive treatment plan
- Does not cause sedation or cognitive impairment during treatment
- Non-addictive with no potential for abuse or dependence
- May help restore neurochemical balance disrupted by chronic alcohol use
- Can be used in conjunction with psychosocial therapies and counseling
Common use
Acamprol 333 mg is primarily used in the management of alcohol dependence in adults who have achieved abstinence and seek to maintain it. It is typically prescribed after the acute withdrawal phase has been completed, usually beginning treatment after the patient has undergone detoxification. The medication is most effective when integrated into a comprehensive treatment program that includes psychological support, counseling, and social rehabilitation. Clinical studies demonstrate its efficacy in reducing relapse rates and supporting long-term recovery when used as directed under medical supervision.
Dosage and direction
The recommended dosage of Acamprol 333 mg for adults is two tablets taken three times daily (total daily dose: 1998 mg). Tablets should be swallowed whole with water and not crushed or chewed. It is preferable to take the medication with meals to improve gastrointestinal tolerance. Treatment should be initiated as soon as possible after the acute withdrawal period and typically continues for as long as the therapeutic effect is maintained. Dosage adjustment may be necessary in patients with moderate renal impairment (creatinine clearance 30-50 mL/min), with a reduction to two tablets twice daily. Not recommended for patients with severe renal impairment (creatinine clearance <30 mL/min).
Precautions
Patients should be monitored regularly during treatment with Acamprol 333 mg. Renal function should be assessed before initiation and periodically during treatment, particularly in elderly patients or those with pre-existing renal conditions. The medication contains calcium, which should be considered in patients requiring calcium restriction. Patients should continue to receive appropriate psychosocial support throughout treatment. Driving and operating machinery may be affected if alcohol is consumed during treatment. The safety and efficacy in patients under 18 years of age have not been established.
Contraindications
Acamprol 333 mg is contraindicated in patients with hypersensitivity to calcium acetylhomotaurinate or any of the excipients. It should not be used in patients with severe renal impairment (creatinine clearance <30 mL/min). The medication is contraindicated during pregnancy unless clearly necessary and under strict medical supervision. It should not be used by breastfeeding women due to insufficient safety data. Concurrent use with disulfiram is not recommended due to limited clinical experience with this combination.
Possible side effects
The most commonly reported side effects include diarrhea, nausea, abdominal pain, and pruritus. These are generally mild to moderate and often diminish with continued treatment. Less frequently reported effects include vomiting, flatulence, decreased libido, and rash. In clinical trials, approximately 10-15% of patients experienced gastrointestinal disturbances, which typically resolved without discontinuation of treatment. Serious side effects are rare but may include severe allergic reactions. Patients should report any persistent or severe symptoms to their healthcare provider.
Drug interaction
No clinically significant pharmacokinetic interactions have been observed with medications commonly used in alcohol dependence treatment. However, caution is advised when administering Acamprol 333 mg with other centrally acting drugs. The absorption of tetracyclines and fluoroquinolones may be reduced due to the calcium content of Acamprol 333 mg; these medications should be taken at least 2 hours before or after Acamprol 333 mg. No interactions with alcohol have been demonstrated, though consumption of alcohol during treatment is countertherapeutic.
Missed dose
If a dose is missed, patients should take it as soon as they remember unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed one. Consistency in dosing is important for maintaining therapeutic effect, so patients should strive to adhere to the prescribed schedule. If multiple doses are missed, patients should consult their healthcare provider for guidance.
Overdose
Cases of overdose with Acamprol 333 mg have been reported rarely. Symptoms may include gastrointestinal disturbances such as diarrhea. In cases of massive overdose, hypercalcemia might occur due to the calcium content. Treatment should be symptomatic and supportive. Gastric lavage may be considered if performed soon after ingestion. Patients should seek immediate medical attention if overdose is suspected. There is no specific antidote for Acamprol 333 mg overdose.
Storage
Store Acamprol 333 mg tablets in their original packaging at room temperature (15-30°C). Protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Proper disposal of unused medication should follow local regulations for pharmaceutical waste.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Acamprol 333 mg is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Patients should not initiate or discontinue treatment without consulting their physician. The full prescribing information should be consulted before use. Individual results may vary, and not all patients will experience the same benefits.
Reviews
Clinical studies have demonstrated that Acamprol 333 mg is effective in maintaining abstinence in alcohol-dependent patients when used as part of a comprehensive treatment program. In randomized controlled trials, patients treated with Acamprol 333 mg showed significantly higher abstinence rates compared to placebo over treatment periods of 6-12 months. Many healthcare providers report satisfactory results in appropriate patients who are motivated to maintain abstinence. Patient experiences vary, with many reporting reduced craving and improved ability to maintain sobriety when combined with psychosocial support.